Cellectar Biosciences (NASDAQ:CLRB) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Cellectar Biosciences (CLRB) operate in?

Cellectar Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cellectar Biosciences Stock (NASDAQ: CLRB) stock price, news, charts, stock research, profile.

Open	$2.61
Close	$2.52
Volume / Avg.	136.23K / 542.84K
Day Range	2.51 - 2.65
52 Wk Range	1.56 - 4.45
Market Cap	$90.04M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	44
Short Interest	7.2%
Days to Cover	2.87

Recent News

Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why

Cellectar Biosciences reports positive Phase 1 trial results for iopofosine I 131 in head and neck squamous cell carcinoma, achieving 64% complete remission and 73% overall response rate. Roth Capital notes the drug's potential across various diseases, positioning CLRB as an attractive acquisition target.

Vandana Singh

Why Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?

Cellectar Biosciences Inc (NASDAQ: CLRB) announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a targeted radiotherapy candidate for the treatment of relapsed/refractory Waldenstrom's macroglobulinemia (WM) patients that have received at

Vandana Singh

Crude Oil Rises 1%; Verb Technology Shares Spike Higher

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling 100 points on Tuesday. The Dow traded down 0.31% to 34,728.66 while the NASDAQ rose 0.11% to 14,047.61. The S&P 500, also fell, dropping, 0.22% to 4,505.65.

Lisa Levin

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

About Cellectar Biosciences Inc

Sector

Health Care

Industry

Biotechnology

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discov...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Cellectar Biosciences (CLRB) stock?

You can purchase shares of Cellectar Biosciences (NASDAQ:CLRB) through any online brokerage.

View our list of the best stock brokerages

Who are Cellectar Biosciences (CLRB) competitors?

Other companies in Cellectar Biosciences’s space includes: Anixa Biosciences (NASDAQ:ANIX), CytomX Therapeutics (NASDAQ:CTMX), T2 Biosystems (NASDAQ:TTOO), FibroGen (NASDAQ:FGEN) and Vistagen Therapeutics (NASDAQ:VTGN).

What is the target price for Cellectar Biosciences (CLRB) stock?

There is no analysis for Cellectar Biosciences.

What is the forecast for Cellectar Biosciences (CLRB) stock?

Cellectar Biosciences has a consensus price target of $14.67.

Current stock price for Cellectar Biosciences (CLRB)?

The stock price for Cellectar Biosciences (NASDAQ: CLRB) is $2.5117 last updated Today at July 19, 2024 at 5:42 PM EDT.

Does Cellectar Biosciences (CLRB) pay a dividend?

There are no upcoming dividends for Cellectar Biosciences.

When is Cellectar Biosciences (NASDAQ:CLRB) reporting earnings?

Cellectar Biosciences’s Q2 earnings are confirmed for Monday, August 12, 2024.

Is Cellectar Biosciences (CLRB) going to split?

There is no upcoming split for Cellectar Biosciences.

What sector and industry does Cellectar Biosciences (CLRB) operate in?

Cellectar Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Cellectar Biosciences

Cellectar Biosciences (CLRB) Forecast